Diagnostic Performance and Comparative Evaluation of the Architect, Liaison, and Platelia Epstein-Barr Virus Antibody Assays

Park, Younhee; Park, Borae G.; Ha, Jihye; Kim, Hyun Sook

doi:10.3343/alm.2018.38.5.458

Cited by 8 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Molecular biological detection has become an essential tool in the diagnosis and monitoring of EBV infection and disease in immunocompromised hosts 9 . Previous studies 10,11 have indicated that serological and molecular biological tests should be used complementarily to diagnose the EBV infection status of patients.…”

Section: Introductionmentioning

confidence: 99%

“…7,8 Molecular biological detection has become an essential tool in the diagnosis and monitoring of EBV infection and disease in immunocompromised hosts. 9 Previous studies 10,11 have indicated that serological and molecular biological tests should be used complementarily to diagnose the EBV infection status of patients. This study combined serological and molecular biological assays with an aim of tracking the characteristics of primary EBV infection disease spectrum and reactivation in children, and further assessing the possible influencing factors of severe EBV-related diseases.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Characteristics of primary Epstein–Barr virus infection disease spectrum and its reactivation in children, in Suzhou, China

Shi

Huang

Tian

2021

Journal of Medical Virology

View full text Add to dashboard Cite

Epstein–Barr virus (EBV) is a globally prevalent herpesvirus associated with multiple diseases. This study aimed to determine the characteristics of primary EBV infection disease spectrum and reactivation in children, in Suzhou, China. All children admitted to the Children's Hospital of Soochow University between May 2018 and September 2020 with suspected EBV‐associated disease and subjected to the indirect immunofluorescence assay for EBV‐specific antibodies and plasma EBV‐DNA assays were included. Of the 3567 children, 2782 (78.0%) tested positive for EBV. The positive rates of viral capsid antigen (VCA)‐IgM, VCA‐IgG, early antigen (EA)‐IgG, nuclear antigen (EBNA)‐IgG, and plasma EBV‐DNA were 12.1%, 74.6%, 37.9%, 35.6%, and 31.1%, respectively. The lowest VCA‐IgG and EBNA‐IgG seropositivity rates occurred at ages between 8 and 36 months, then increased gradually in the older age groups. The EBV‐IgM seropositivity rate was the highest in those aged 36 to <72 months. Primary EBV infection was more common in children aged 36 to <72 months. In past infections, reactivation mainly occurred in 8 to <36 months. The most common disease caused by primary EBV infection was infectious mononucleosis (56.1%), followed by a respiratory infection (17.0%). Respiratory infection (30.0%), EBV infection (29.2%), and hemophagocytic lymphohistiocytosis (HLH) (15.8%) were the commonest diseases caused by EBV reactivation. EBV reactivation was a risk factor for HLH (adjusted odds ratio, 16.4; 95% confidence interval, 7.9–34.0). Among reactivated patients, the viral load of HLH was higher than that of EBV infection and respiratory infection (p < .01). This is a retrospective large sample study that explored the characteristics of primary EBV infection disease spectrum and reactivation in children.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Characteristics of primary Epstein–Barr virus infection disease spectrum and its reactivation in children, in Suzhou, China

Shi

Huang

Tian

2021

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…16 Plasma EBV-DNA detection is the direct evidence of virus infection and activity, and its load reflects the ability of virus replication and host immune clearance. Previous studies 17,18 have indicated that EBV DNA and antibody assays should be used complementarily to diagnose the EBV infection status of patients. In addition, primary EBV infection will lead to an activation of cytotoxic T-lymphocytes, then lymphocytes increase and atypical lymphocytes appear in peripheral blood.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of serological and molecular biological tests for infectious mononucleosis by EBV in different age stages and course of the disease

Shi

Huang

Luo

et al. 2020

Journal of Medical Virology

View full text Add to dashboard Cite

Epstein‐Barr virus (EBV)‐based serologic antibody and viral nucleic acid assays have been found to be feasible means to diagnose infectious mononucleosis (IM) caused by EBV in children. In this study, we will further explore their diagnostic value for IM by EBV in different age stages and over the course of the disease. A collection of 616 children from clinically suspected IM cases was studied. Indirect immunofluorescence (IIF) for EBV‐specific antibody (Euroimmun) combined with plasma EB viral nucleic acid assay (real‐time fluorescence quantitative polymerase chain reaction reverse‐transcription polymerase chain reaction) were used as reference methods. The diagnostic efficiency of the peripheral blood routine test, serologic antibody test, and plasma EB viral nucleic acid assay for the diagnosis of IM was evaluated, respectively. The sensitivity, specificity, Youden' index and the area under curve (AUC) were 93.08%, 87.77%, 0.81 and 0.904 (95% confidence interval [CI]: 0.878–0.931) for the peripheral lymphocyte test (lymphocytosis > 5 × 109/L), 98.27%, 91.13%, 0.89 and 0.947 (95% CI: 0.927–0.967) for the plasma EBV‐DNA test, and 84.08%, 96.33%, 0.80 and 0.902 (95% CI: 0.874–0.930) for the EBV viral capsid antigen (VCA)‐IgG avidity test. The plasma EBV‐DNA test has a higher diagnostic value than the VCA‐IgG avidity test in children aged <6 years, especially aged <3 years; the peripheral lymphocyte test and plasma EBV‐DNA test are suitable for the early stage of the disease, while the VCA‐IgG avidity test for after 7 days of the disease. EBV antibody detection (IIF) should be combined with EBV nucleic acid detection in children age <6 years and the early stage of the disease.

show abstract

“…The first two assays have been presently rarely used, while ELISA is currently the most commonly used. However, the sensitivity and specificity of the assay need to be improved, and the detection performance of kits from different manufacturers varies [9,14,15] . CLIA is a novel technique of ELISA, which replaces the traditional color substrate with chemiluminescence substrate and characterized by enhancing the luminescence signal by enzyme, and stabilizing and prolonging the luminescence signal time.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Chemiluminescence Immunoassays on VCA-IgA and EBNA1-IgA Antibodies of Epstein-Barr Virus in Diagnosing Nasopharyngeal Carcinoma

Xia¹,

Li²,

Cheng³

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: IgA antibodies against Epstein-Barr virus (EBV) capsid antigen (VCA) and nuclear antigen 1 (EBNA1) have been proposed to facilitate the diagnosis and early detection of nasopharyngeal carcinoma (NPC) in high-incidence regions. However, while new methodologies and new platforms for the detection of VCA-IgA and EBNA1-IgA have become available, proper interassay simultaneous comparisons have not been carried out. The study was to compare the performance of the chemiluminescent immunoassays (CLIA) and enzyme-linked immunosorbent assay (ELISA) for VCA-IgA and EBNA1-IgA antibodies, and to evaluate the levels of EBV antibodies in healthy population from different areas of China. Methods: CLIA and ELISA for VCA-IgA and EBNA1-IgA were performed in NPC and healthy populations from high-incidence areas of NPC in South China (N=555), medium-incidence areas of NPC in Central China (N=318) and low-incidence areas of NPC in North China (N=379), and the results were compared and analyzed. Results: (1) The highest sensitivity in total, early and advanced NPC were 91.5% (CLIA for VCA-IgA), 86.4% (CLIA and ELISA-2 for EBNA1-IgA) and 93.6% (CLIA for VCA-IgA). However, the specificity of EBV-IgA measured by CLIA was relatively lower than ELISA. The top three seromarkers with the largest AUC was CLIA for VCA-IgA (AUC: 0.929, 95% CI: 0.905-0.953), ELISA-2 for EBNA1-IgA (AUC: 0.922, 95% CI: 0.896-0.947) and CLIA for EBNA1-IgA (AUC:0.919, 95% CI: 0.893-0.945), respectively. The positive and negative coincidence rates of the two EBNA1-IgA kits were 69.5% and 91.9%, respectively. However, the coincidence rates of VCA-IgA were relatively low. CLIA kits had good repeatability between different laboratories. (2) The positive rates of EBV-IgA antibodies were relatively high in high-incidence areas of NPC (P < 0.017), while there was no significant difference in the antibody positive rates between medium-incidence areas and low-incidence areas of NPC (P > 0.05).

show abstract

Diagnostic Performance and Comparative Evaluation of the Architect, Liaison, and Platelia Epstein-Barr Virus Antibody Assays

Cited by 8 publications

References 16 publications

Characteristics of primary Epstein–Barr virus infection disease spectrum and its reactivation in children, in Suzhou, China

Characteristics of primary Epstein–Barr virus infection disease spectrum and its reactivation in children, in Suzhou, China

Diagnostic value of serological and molecular biological tests for infectious mononucleosis by EBV in different age stages and course of the disease

Efficacy of Chemiluminescence Immunoassays on VCA-IgA and EBNA1-IgA Antibodies of Epstein-Barr Virus in Diagnosing Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About